NCT04652557View on ClinicalTrials.gov

Influence of Fampridine on Working Memory in Healthy Young Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

January 26, 2023

Study Completion Date

January 26, 2023

Conditions
Working Memory
Interventions
DRUG

Fampridine SR

Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).

DRUG

Placebo

no active component

Trial Locations (1)

4055

University of Basel, Transfaculty Research Platform, Basel

All Listed Sponsors
collaborator

Clinical Trial Unit, University Hospital Basel, Switzerland

OTHER

collaborator

University Hospital, Basel, Switzerland

OTHER

lead

Prof. Dominique de Quervain, MD

OTHER

NCT04652557 - Influence of Fampridine on Working Memory in Healthy Young Subjects | Biotech Hunter | Biotech Hunter